Lucid Diagnostics (LUCD) Competitors

$1.07 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.07 +0.00 (+0.28%)

As of 05/22/2026 07:54 PM Eastern

LUCD vs. AVR, SGP, SIBN, CBLL, and BWAY

Should you buy Lucid Diagnostics stock or one of its competitors? MarketBeat compares Lucid Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lucid Diagnostics include Anteris Technologies Global (AVR), Spyglass Pharma (SGP), SiBone (SIBN), CeriBell (CBLL), and Brainsway (BWAY). These companies are all part of the "medical equipment" industry.

How does Lucid Diagnostics compare to Anteris Technologies Global?

Lucid Diagnostics (NASDAQ:LUCD) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

74.0% of Lucid Diagnostics shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 4.5% of Anteris Technologies Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Anteris Technologies Global had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for Anteris Technologies Global and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.96 beat Anteris Technologies Global's score of -0.20 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Anteris Technologies Global	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lucid Diagnostics presently has a consensus price target of $4.13, suggesting a potential upside of 285.51%. Anteris Technologies Global has a consensus price target of $16.00, suggesting a potential upside of 66.32%. Given Lucid Diagnostics' higher possible upside, equities analysts clearly believe Lucid Diagnostics is more favorable than Anteris Technologies Global.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Anteris Technologies Global	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Lucid Diagnostics has higher revenue and earnings than Anteris Technologies Global. Anteris Technologies Global is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A
Anteris Technologies Global	$1.91M	490.27	-$94.14M	-$2.23	N/A

Lucid Diagnostics has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Anteris Technologies Global has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

Lucid Diagnostics has a net margin of -876.72% compared to Anteris Technologies Global's net margin of -5,148.78%. Lucid Diagnostics' return on equity of 0.00% beat Anteris Technologies Global's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Anteris Technologies Global	-5,148.78%	-124.76%	-101.21%

Summary

Lucid Diagnostics beats Anteris Technologies Global on 10 of the 14 factors compared between the two stocks.

How does Lucid Diagnostics compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Spyglass Pharma has higher earnings, but lower revenue than Lucid Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A

Spyglass Pharma has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Lucid Diagnostics	-876.72%	N/A	-116.26%

Spyglass Pharma presently has a consensus target price of $45.00, indicating a potential upside of 115.93%. Lucid Diagnostics has a consensus target price of $4.13, indicating a potential upside of 285.51%. Given Lucid Diagnostics' higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

74.0% of Lucid Diagnostics shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Spyglass Pharma and Spyglass Pharma both had 2 articles in the media. Lucid Diagnostics' average media sentiment score of 1.96 beat Spyglass Pharma's score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Lucid Diagnostics beats Spyglass Pharma on 5 of the 9 factors compared between the two stocks.

How does Lucid Diagnostics compare to SiBone?

SiBone (NASDAQ:SIBN) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

SiBone has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

98.1% of SiBone shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 4.0% of SiBone shares are owned by company insiders. Comparatively, 6.8% of Lucid Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

SiBone has higher revenue and earnings than Lucid Diagnostics. SiBone is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.24	-$18.90M	-$0.39	N/A
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A

SiBone has a net margin of -8.10% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Lucid Diagnostics	-876.72%	N/A	-116.26%

SiBone presently has a consensus target price of $23.00, indicating a potential upside of 56.68%. Lucid Diagnostics has a consensus target price of $4.13, indicating a potential upside of 285.51%. Given Lucid Diagnostics' higher probable upside, analysts plainly believe Lucid Diagnostics is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, SiBone had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 4 mentions for SiBone and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.96 beat SiBone's score of -0.70 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

SiBone beats Lucid Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Lucid Diagnostics compare to CeriBell?

Lucid Diagnostics (NASDAQ:LUCD) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Lucid Diagnostics has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

CeriBell has a net margin of -63.51% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
CeriBell	-63.51%	-38.19%	-30.92%

In the previous week, Lucid Diagnostics and Lucid Diagnostics both had 2 articles in the media. Lucid Diagnostics' average media sentiment score of 1.96 beat CeriBell's score of 0.20 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CeriBell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lucid Diagnostics currently has a consensus target price of $4.13, suggesting a potential upside of 285.51%. CeriBell has a consensus target price of $22.20, suggesting a potential upside of 18.27%. Given Lucid Diagnostics' higher possible upside, equities analysts plainly believe Lucid Diagnostics is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

CeriBell has higher revenue and earnings than Lucid Diagnostics. CeriBell is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A
CeriBell	$89.06M	8.00	-$53.41M	-$1.63	N/A

74.0% of Lucid Diagnostics shares are held by institutional investors. 6.8% of Lucid Diagnostics shares are held by insiders. Comparatively, 20.1% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Lucid Diagnostics beats CeriBell on 8 of the 15 factors compared between the two stocks.

How does Lucid Diagnostics compare to Brainsway?

Lucid Diagnostics (NASDAQ:LUCD) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

In the previous week, Lucid Diagnostics had 1 more articles in the media than Brainsway. MarketBeat recorded 2 mentions for Lucid Diagnostics and 1 mentions for Brainsway. Lucid Diagnostics' average media sentiment score of 1.96 beat Brainsway's score of 0.00 indicating that Lucid Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Brainsway	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lucid Diagnostics has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market.

Brainsway has a net margin of 15.68% compared to Lucid Diagnostics' net margin of -876.72%. Brainsway's return on equity of 12.28% beat Lucid Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Brainsway	15.68%	12.28%	7.75%

Brainsway has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$4.71M	46.13	-$58.01M	-$0.47	N/A
Brainsway	$52.22M	11.58	$7.57M	$0.35	43.14

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 6.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lucid Diagnostics presently has a consensus target price of $4.13, indicating a potential upside of 285.51%. Brainsway has a consensus target price of $15.00, indicating a potential downside of 0.66%. Given Lucid Diagnostics' higher probable upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Brainsway beats Lucid Diagnostics on 10 of the 16 factors compared between the two stocks.

Get Lucid Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUCD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUCD vs. The Competition

Export

Metric	Lucid Diagnostics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$217.28M	$7.10B	$6.46B	$12.34B
Dividend Yield	N/A	1.68%	2.76%	5.28%
P/E Ratio	-2.28	47.45	21.00	25.66
Price / Sales	46.13	73.72	558.19	86.31
Price / Cash	N/A	24.91	43.49	56.67
Price / Book	-35.67	6.53	10.40	7.14
Net Income	-$58.01M	$158.81M	$3.57B	$335.98M
7 Day Performance	12.99%	3.61%	6.40%	4.11%
1 Month Performance	N/A	0.74%	3.55%	2.52%
1 Year Performance	-32.70%	3.17%	34.13%	35.04%

Lucid Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUCD Lucid Diagnostics	4.3729 of 5 stars	$1.07 flat	$4.13 +285.5%	-32.7%	$217.28M	$4.71M	N/A	70
AVR Anteris Technologies Global	3.1083 of 5 stars	$7.70 +1.7%	$16.00 +107.8%	+164.3%	$736.88M	$1.91M	N/A	138	Gap Down High Trading Volume
SGP Spyglass Pharma	N/A	$21.20 -4.7%	$45.00 +112.3%	N/A	$708.65M	N/A	N/A	65	Negative News
SIBN SiBone	2.3468 of 5 stars	$14.84 +0.5%	$23.00 +55.0%	-20.1%	$654.59M	$200.93M	N/A	350
CBLL CeriBell	1.9473 of 5 stars	$16.96 +2.3%	$22.20 +30.9%	+13.2%	$629.09M	$89.06M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUCD) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lucid Diagnostics (LUCD) Competitors

LUCD vs. AVR, SGP, SIBN, CBLL, and BWAY

How does Lucid Diagnostics compare to Anteris Technologies Global?

Summary

How does Lucid Diagnostics compare to Spyglass Pharma?

Summary

How does Lucid Diagnostics compare to SiBone?

Summary

How does Lucid Diagnostics compare to CeriBell?

Summary

How does Lucid Diagnostics compare to Brainsway?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lucid Diagnostics (LUCD) Competitors

LUCD vs. AVR, SGP, SIBN, CBLL, and BWAY

How does Lucid Diagnostics compare to Anteris Technologies Global?

Do insiders & institutionals believe in LUCD or AVR?

Does the media prefer LUCD or AVR?

Do analysts recommend LUCD or AVR?

Which has higher earnings & valuation, LUCD or AVR?

Which has more risk and volatility, LUCD or AVR?

Is LUCD or AVR more profitable?

Summary

How does Lucid Diagnostics compare to Spyglass Pharma?

Which has better valuation and earnings, SGP or LUCD?

Is SGP or LUCD more profitable?

Do analysts recommend SGP or LUCD?

Do institutionals and insiders believe in SGP or LUCD?

Does the media refer more to SGP or LUCD?

Summary

How does Lucid Diagnostics compare to SiBone?

Which has more volatility & risk, SIBN or LUCD?

Do institutionals & insiders have more ownership in SIBN or LUCD?

Which has stronger valuation and earnings, SIBN or LUCD?

Is SIBN or LUCD more profitable?

Do analysts rate SIBN or LUCD?

Does the media favor SIBN or LUCD?

Summary

How does Lucid Diagnostics compare to CeriBell?

Which has more volatility & risk, LUCD or CBLL?

Is LUCD or CBLL more profitable?

Does the media refer more to LUCD or CBLL?

Do analysts prefer LUCD or CBLL?

Which has better earnings and valuation, LUCD or CBLL?

Do institutionals and insiders hold more shares of LUCD or CBLL?

Summary

How does Lucid Diagnostics compare to Brainsway?

Does the media refer more to LUCD or BWAY?

Which has more risk and volatility, LUCD or BWAY?

Is LUCD or BWAY more profitable?

Which has preferable earnings & valuation, LUCD or BWAY?

Do institutionals and insiders believe in LUCD or BWAY?

Do analysts recommend LUCD or BWAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD vs. The Competition

Lucid Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools